Physician

Sofyan Morshed Taleb Radaideh, MD

According to 2025 Medicare claims, Sofyan Radaideh, MD (NPI: 1477711901) practices hematology/oncology in the Pueblo, CO market, with the plurality of this provider's patient population coming from Pueblo, CO. This provider's primary affiliated billing organization is ROCKY MOUNTAIN CANCER CENTERS LLP (NPI: 1518941186; TIN: 841457488) and primary practice location at 81003-9998. Radaideh is affiliated with the CommonSpirit ACO I (ACO ID: A2164) and Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Radaideh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 474 traditional Medicare patients, billed 122,530 HCPCS/CPT codes, and received $2,323,684 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 656 prescription claims across 136 beneficiaries totaling $2,549,172 in drug costs, led by Revlimid (Lenalidomide). DME data shows 13 claims. Open Payments data shows 1 records totaling $1,350. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $908,521 to $2,323,684. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $750,895 to $2,549,172. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $6,821 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.2M$2.3M2015 Medicare payment: $908,521 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $1,474,451 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $1,716,046 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $1,953,976 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $1,733,642 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $2,195,493 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $2,046,118 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $1,857,976 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $2,040,957 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $2,323,684 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
201569071,059$908,521
2016836107,895$1,474,451
2017840113,274$1,716,046
2018750136,158$1,953,976
2019639140,091$1,733,642
2020577142,824$2,195,493
2021513136,332$2,046,118
2022502144,214$1,857,976
2023450130,433$2,040,957
2024474122,530$2,323,684

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$1.4M$2.8M2015 Drug cost: $750,895 (USD; Tot_Drug_Cst)2016 Drug cost: $1,069,900 (USD; Tot_Drug_Cst)2017 Drug cost: $778,218 (USD; Tot_Drug_Cst)2018 Drug cost: $1,260,480 (USD; Tot_Drug_Cst)2019 Drug cost: $1,301,490 (USD; Tot_Drug_Cst)2020 Drug cost: $1,922,380 (USD; Tot_Drug_Cst)2021 Drug cost: $2,091,179 (USD; Tot_Drug_Cst)2022 Drug cost: $2,840,892 (USD; Tot_Drug_Cst)2023 Drug cost: $2,467,165 (USD; Tot_Drug_Cst)2024 Drug cost: $2,549,172 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015154614$750,895
2016167640$1,069,900
2017152638$778,218
2018155649$1,260,480
2019143574$1,301,490
2020143631$1,922,380
2021149628$2,091,179
2022154771$2,840,892
2023138616$2,467,165
2024136656$2,549,172

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

DME Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: DME_Suplr_Mdcr_Pymt_Amt. Source: Medicare DME, Devices & Supplies by Referring Provider.0$41K$81K2015 Medicare payment: $81,002 (USD; DME_Suplr_Mdcr_Pymt_Amt)2016 Medicare payment: $18,586 (USD; DME_Suplr_Mdcr_Pymt_Amt)2017 Medicare payment: $7,005 (USD; DME_Suplr_Mdcr_Pymt_Amt)2018 Medicare payment: $245 (USD; DME_Suplr_Mdcr_Pymt_Amt)2019 Medicare payment: $5,865 (USD; DME_Suplr_Mdcr_Pymt_Amt)2022 Medicare payment: $2,081 (USD; DME_Suplr_Mdcr_Pymt_Amt)2023 Medicare payment: $10,668 (USD; DME_Suplr_Mdcr_Pymt_Amt)2024 Medicare payment: $245 (USD; DME_Suplr_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClaimsPayment
2015N/R175$81,002
2016N/R76$18,586
2017N/R25$7,005
2018N/R13$245
2019N/R48$5,865
2020N/RN/RN/R
2021N/RN/RN/R
2022N/R45$2,081
2023N/R28$10,668
2024N/R13$245

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
96413Administration of chemotherapy into vein, 1 hour or less128307$102
G2211Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's155268$13
80053Blood test, comprehensive group of blood chemicals168514$10
36415Insertion of needle into vein for collection of blood sample214668$9
85025Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count211646$8

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
RevlimidLenalidomide421,176$837,572
LenalidomideLenalidomide26728$369,816
PomalystPomalidomide12336$318,845
EverolimusEverolimus13366$23,006
Abiraterone AcetateAbiraterone Acetate361,080$19,464

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS CodeHCPCS DescriptionSupplier Rental IndicatorTotal Supplier BeneficiariesTotal Supplier ClaimsTotal Medicare Payment Amount
Q0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day periodNN/R13$245

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.0$0N/R
Research PaymentsReported research-related payment or transfer-of-value amount.1$1,350Takeda Pharmaceuticals U.S.A., Inc.
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Sofyan Morshed Taleb Radaideh, MD?

Tedicare shows public-source Medicare data for Sofyan Morshed Taleb Radaideh, MD (NPI 1477711901), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sofyan Morshed Taleb Radaideh, MD have ACO affiliation data?

Sofyan Morshed Taleb Radaideh, MD is shown with ACO affiliation data for CommonSpirit ACO I (MSSP, ACO ID A2164) and Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Sofyan Morshed Taleb Radaideh, MD?

Sofyan Morshed Taleb Radaideh, MD is linked to ROCKY MOUNTAIN CANCER CENTERS LLP (billing NPI 1518941186) in the available physician profile data.

Does Sofyan Morshed Taleb Radaideh, MD have Open Payments data?

Sofyan Morshed Taleb Radaideh, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.